These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 20601020)

  • 21. Heart rate correction models to detect QT interval prolongation in novel pharmaceutical development.
    Markert M; Shen R; Trautmann T; Guth B
    J Pharmacol Toxicol Methods; 2011; 64(1):25-41. PubMed ID: 21635956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14/S7B Q&As.
    Rossman EI; Wisialowski TA; Vargas HM; Valentin JP; Rolf MG; Roche BM; Riley S; Pugsley MK; Nichols J; Li D; Leishman DJ; Kleiman RB; Greiter-Wilke A; Gintant GA; Engwall MJ; Delaunois A; Authier S
    J Pharmacol Toxicol Methods; 2023; 123():107270. PubMed ID: 37164235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The fentanyl/etomidate-anaesthetised beagle (FEAB) dog: a versatile in vivo model in cardiovascular safety research.
    Van Deuren B; Van Ammel K; Somers Y; Cools F; Straetemans R; van der Linde HJ; Gallacher DJ
    J Pharmacol Toxicol Methods; 2009; 60(1):11-23. PubMed ID: 19422925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates.
    Guo L; Dong Z; Guthrie H
    J Pharmacol Toxicol Methods; 2009; 60(2):130-51. PubMed ID: 19616638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methods in safety pharmacology in focus.
    Pugsley MK; Gallacher DJ; Towart R; Authier S; Curtis MJ
    J Pharmacol Toxicol Methods; 2008; 58(2):69-71. PubMed ID: 18707009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do Studies Evaluating QT/QTc Interval Prolongation with Dietary Supplements Meet FDA Standards: A Systematic Review.
    Nguyen TA; Kurian A; Leong J; Patel UM; Shah SA
    J Diet Suppl; 2017 Jul; 14(4):467-477. PubMed ID: 27937000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ILSI-HESI cardiovascular safety subcommittee dataset: an analysis of the statistical properties of QT interval and rate-corrected QT interval (QTc).
    Chiang AY; Bass AS; Cooper MM; Engwall MJ; Menton RG; Thomas K
    J Pharmacol Toxicol Methods; 2007; 56(2):95-102. PubMed ID: 17588780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance characteristics for some typical QT study designs under the ICH E-14 guidance.
    Hutmacher MM; Chapel S; Agin MA; Fleishaker JC; Lalonde RL
    J Clin Pharmacol; 2008 Feb; 48(2):215-24. PubMed ID: 18199896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of group housing on ECG assessment in conscious cynomolgus monkeys.
    Xing G; Lu J; Hu M; Wang S; Zhao L; Zheng W; Schofield J; Oldman K; Adkins D; Yu H; Platz S; Ren J; Skinner M
    J Pharmacol Toxicol Methods; 2015; 75():44-51. PubMed ID: 25979821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The anesthetized guinea pig: an effective early cardiovascular derisking and lead optimization model.
    Morissette P; Nishida M; Trepakova E; Imredy J; Lagrutta A; Chaves A; Hoagland K; Hoe CM; Zrada MM; Travis JJ; Zingaro GJ; Gerenser P; Friedrichs G; Salata JJ
    J Pharmacol Toxicol Methods; 2013; 68(1):137-49. PubMed ID: 23649000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing proarrhythmic potential of drugs when optimal studies are infeasible.
    Rock EP; Finkle J; Fingert HJ; Booth BP; Garnett CE; Grant S; Justice RL; Kovacs RJ; Kowey PR; Rodriguez I; Sanhai WR; Strnadova C; Targum SL; Tsong Y; Uhl K; Stockbridge N
    Am Heart J; 2009 May; 157(5):827-36, 836.e1. PubMed ID: 19376308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of an algorithm for highly automated measurements of QT interval.
    Brockway M; Hamlin R
    J Pharmacol Toxicol Methods; 2011; 64(1):16-24. PubMed ID: 21640193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recalibration of nonclinical safety pharmacology assessment to anticipate evolving regulatory expectations.
    Pugsley MK; Authier S; Hayes ES; Hamlin RL; Accardi MV; Curtis MJ
    J Pharmacol Toxicol Methods; 2016; 81():1-8. PubMed ID: 27343819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing methods of measurement for detecting drug-induced changes in the QT interval: implications for thoroughly conducted ECG studies.
    Azie NE; Adams G; Darpo B; Francom SF; Polasek EC; Wisser JM; Fleishaker JC
    Ann Noninvasive Electrocardiol; 2004 Apr; 9(2):166-74. PubMed ID: 15084215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Research implications of the FDA ECG warehouse and related resources.
    Green CL
    J Electrocardiol; 2019; 57S():S27-S33. PubMed ID: 31627942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Creation of a knowledge management system for QT analyses.
    Tornøe CW; Garnett CE; Wang Y; Florian J; Li M; Gobburu JV
    J Clin Pharmacol; 2011 Jul; 51(7):1035-42. PubMed ID: 20978278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular parameters in anaesthetized guinea pigs: a safety pharmacology screening model.
    Hauser DS; Stade M; Schmidt A; Hanauer G
    J Pharmacol Toxicol Methods; 2005; 52(1):106-14. PubMed ID: 15961325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous solid tip ECG lead placement in telemetry implanted dogs: Part 2: High quality telemetry signals yield high sensitivity to drug-induced changes.
    Mitchell AZ; Bills AJ; Wittwer GT; Foley CM; Kremer JJ; Chen H; Osinski MA
    J Pharmacol Toxicol Methods; 2013; 68(1):62-73. PubMed ID: 23639348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of cardiovascular changes in dogs administered three positive controls using jacketed external telemetry-blood pressure (JET-BP).
    Kremer JJ; Bills AJ; Hanke NJ; Chen H; Meier WA; Osinski MA; Foley CM
    J Pharmacol Toxicol Methods; 2015; 75():27-37. PubMed ID: 26001324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The importance of electrocardiography in the development of new drugs--prolonged QT intervals as indicators of adverse effects].
    Jerie P; Vít P
    Vnitr Lek; 2002 Dec; 48 Suppl 1():114-9. PubMed ID: 12744031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.